Literature DB >> 14686489

Immunology of B7-H1 and its roles in human diseases.

Hideto Tamura1, Kiyoyuki Ogata, Haidong Dong, Lieping Chen.   

Abstract

B7-H1 was originally identified by homology analysis in comparison with B7-1 and B7-2, two molecules with important immunoregulatory functions. B7-H1, however, was broadly induced in the majority of peripheral tissues as well as hematopoietic cells. Upon binding to an as yet unidentified costimulatory receptor on primed T-cells, B7-H1 costimulates T-cell proliferation and preferentially induces interleukin 10 and interferon gamma. The costimulatory function of B7-H1 may be critical for enhancing maturation and differentiation of T-cells in lymphoid organs. Conversely, by binding to programmed death 1 receptors on activated T-cells and B-cells, B7-H1 may inhibit ongoing T-cell responses in peripheral tissues by inducing apoptosis and arresting cell-cycle progression. Although a positive regulatory role of B7-H1 has been demonstrated in vitro and in various animal models, a negative regulatory role of B7-H1 has also been documented in human diseases, including cancer, rheumatoid arthritis, and human immunodeficiency virus infection. Delineation of the complex interactions between B7-H1 and its receptors as well as its interplay with other ligands is critical for understanding this new immunoregulatory system. Precise manipulation of B7-H1 and its receptors may provide unique opportunities for designing new disease treatments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14686489     DOI: 10.1007/BF02983556

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  53 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 2.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

3.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

Authors:  Masayoshi Ishida; Yoshiko Iwai; Yoshimasa Tanaka; Taku Okazaki; Gordon J Freeman; Nagahiro Minato; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-21       Impact factor: 3.685

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha.

Authors:  M M Swallow; J J Wallin; W C Sha
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

6.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

7.  Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS.

Authors:  S K Yoshinaga; M Zhang; J Pistillo; T Horan; S D Khare; K Miner; M Sonnenberg; T Boone; D Brankow; T Dai; J Delaney; H Han; A Hui; T Kohno; R Manoukian; J S Whoriskey; M A Coccia
Journal:  Int Immunol       Date:  2000-10       Impact factor: 4.823

8.  The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia.

Authors:  A Maeda; K Yamamoto; K Yamashita; K Asagoe; M Nohgawa; K Kita; H Iwasaki; T Ueda; A Takahashi; M Sasada
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

9.  B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.

Authors:  L Chen; P McGowan; S Ashe; J V Johnston; I Hellström; K E Hellström
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  6 in total

Review 1.  Cancer-associated myeloproliferation: old association, new therapeutic target.

Authors:  Ryan A Wilcox
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

2.  Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Zhen-Kui Pan; Feng Ye; Xuan Wu; Han-Xiang An; Jing-Xun Wu
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 3.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

4.  Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells.

Authors:  Ellen J Beswick; Irina V Pinchuk; Soumita Das; Don W Powell; Victor E Reyes
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

5.  B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma.

Authors:  Odey C Ukpo; Wade L Thorstad; James S Lewis
Journal:  Head Neck Pathol       Date:  2012-11-20

Review 6.  Type I Interferon at the Interface of Antiviral Immunity and Immune Regulation: The Curious Case of HIV-1.

Authors:  Adriano Boasso
Journal:  Scientifica (Cairo)       Date:  2013-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.